Health Care & Life Sciences » Biotechnology | Macrogenics Inc.

Macrogenics Inc. | Mutual Funds

Mutual Funds that own Macrogenics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
BB Biotech AG
2,600,412
6.16%
200,000
1.37%
03/31/2018
Oppenheimer Global Fund
2,088,320
4.94%
33,756
0.39%
03/31/2018
Fidelity Select Biotechnology Portfolio
1,666,472
3.95%
-334,748
0.4%
07/31/2018
Vanguard Total Stock Market Index Fund
927,097
2.19%
0
0%
07/31/2018
SPDR S&P Biotech ETF
866,772
2.04%
2,229
0.32%
09/06/2018
iShares Russell 2000 ETF
820,476
1.94%
-438
0.04%
09/06/2018
Wasatch Small Cap Growth Fund
546,626
1.29%
0
0.57%
03/31/2018
JNL/Oppenheimer Global Growth Series
501,120
1.19%
20,150
0.4%
03/31/2018
Oppenheimer Variable - Global Fund
501,080
1.19%
-13,710
0.39%
03/31/2018
Vanguard Extended Market Index Fund
492,232
1.17%
8,100
0.02%
07/31/2018

About Macrogenics

View Profile
Address
9740 Medical Center Drive
Rockville Maryland 20850
United States
Employees -
Website http://www.macrogenics.com
Updated 07/08/2019
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its portfolio includes Margetuximab, Flotetuzumab, MGA012, MGD013, Enoblituzumab, MGD009, and Teplizumab. The company was founded by Scott E.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.